文献速递糖尿病

DEVOTE研究中逐日空腹血糖变异性与严重低血糖及心血管结局的关联(DEVOTE 2)

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
PubMed 文献 · Diabetologia · 2017-09-15

DEVOTE 2 是 DEVOTE 试验的二次分析,基于每日早餐前自我血糖监测计算逐日空腹血糖变异性,并在汇总人群中用 Cox 模型分析其与严重低血糖、主要不良心血管事件(MACE)及全因死亡的关系。结果显示,逐日空腹血糖变异性与严重低血糖(HR 4.11,95%CI 3.15, 5.35)、MACE(HR 1.36,95%CI 1.12, 1.65)及全因死亡(HR 1.58,95%CI 1.23, 2.03)相关;校正基线特征及基线 HbA1c 或试验期间最近一次 HbA1c 后,与 MACE 的显著关联未维持。

要点

  • 逐日空腹血糖变异性与严重低血糖风险升高相关(HR 4.11,95%CI 3.15, 5.35)。
  • 逐日空腹血糖变异性与全因死亡风险升高相关(HR 1.58,95%CI 1.23, 2.03)。
  • 校正基线 HbA1c 或最近 HbA1c 后,与 MACE 的关联未达统计学显著。

核心结论

  • 较高的逐日空腹血糖变异性与严重低血糖和全因死亡风险增加相关。

研究设计与样本

  • DEVOTE 为双盲、随机、事件驱动、治疗达标的前瞻性试验,比较德谷胰岛素与甘精胰岛素 U100(100 单位/ml)在心血管事件高风险 2 型糖尿病患者中的心血管安全性。
  • 本文为二次分析,汇总试验人群,采用 Cox 比例风险模型分析逐日空腹血糖变异性与严重低血糖、MACE 及全因死亡的关联。
  • 逐日空腹血糖变异性基于早餐前自我血糖监测(SMBG)测量值的标准差计算:每月仅使用接触研究中心前记录的 3 次早餐前 SMBG 测量值,对 3 次对数转换后的测量值求方差,取各月方差均值的平方根作为逐日空腹血糖变异性。
  • 进行了多项敏感性分析,包括校正基线特征和最近一次 HbA1c。

主要发现

  • 校正前,逐日空腹血糖变异性与严重低血糖相关(HR 4.11,95%CI 3.15, 5.35)。
  • 校正前,逐日空腹血糖变异性与 MACE 相关(HR 1.36,95%CI 1.12, 1.65)。
  • 校正前,逐日空腹血糖变异性与全因死亡相关(HR 1.58,95%CI 1.23, 2.03)。
  • 当患者的逐日空腹血糖变异性测量值加倍时,严重低血糖、MACE 和全因死亡的风险分别增至 2.7 倍、1.2 倍和 1.4 倍。
  • 校正后,逐日空腹血糖变异性与严重低血糖和全因死亡的显著关联维持;校正基线特征及基线 HbA1c 后与 MACE 的关联未维持(HR 1.19,95%CI 0.96, 1.47),校正基线特征及试验期间最近一次 HbA1c 后亦未维持(HR 1.21,95%CI 0.98, 1.49)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE) was a double-blind, randomised, event-driven, treat-to-target prospective trial comparing the cardiovascular safety of insulin degludec with that of insulin glargine U100 (100 units/ml) in patients with type 2 diabetes at high risk of cardiovascular events. This paper reports a secondary analysis investigating associations of day-to-day fasting glycaemic variability (pre-breakfast self-measured blood glucose [SMBG]) with severe hypoglycaemia and cardiovascular outcomes. METHODS: In DEVOTE, patients with type 2 diabetes were randomised to receive insulin degludec or insulin glargine U100 once daily. The primary outcome was the first occurrence of an adjudicated major adverse cardiovascular event (MACE). Adjudicated severe hypoglycaemia was the pre-specified secondary outcome. In this article, day-to-day fasting glycaemic variability was based on the standard deviation of the pre-breakfast SMBG measurements. The variability measure was calculated as follows. Each month, only the three pre-breakfast SMBG measurements recorded before contact with the site were used to determine a day-to-day fasting glycaemic variability measure for each patient. For each patient, the variance of the three log-transformed pre-breakfast SMBG measurements each month was determined. The standard deviation was determined as the square root of the mean of these monthly variances and was defined as day-to-day fasting glycaemic variability. The associations between day-to-day fasting glycaemic variability and severe hypoglycaemia, MACE and all-cause mortality were analysed for the pooled trial population with Cox proportional hazards models. Several sensitivity analyses were conducted, including adjustments for baseline characteristics and most recent HbA1c. RESULTS: Day-to-day fasting glycaemic variability was significantly associated with severe hypoglycaemia (HR 4.11, 95% CI 3.15, 5.35), MACE (HR 1.36, 95% CI 1.12, 1.65) and all-cause mortality (HR 1.58, 95% CI 1.23, 2.03) before adjustments. The increased risks of severe hypoglycaemia, MACE and all-cause mortality translate into 2.7-, 1.2- and 1.4-fold risk, respectively, when a patient's day-to-day fasting glycaemic variability measure is doubled. The significant relationships of day-to-day fasting glycaemic variability with severe hypoglycaemia and all-cause mortality were maintained after adjustments. However, the significant association with MACE was not maintained following adjustment for baseline characteristics with either baseline HbA1c (HR 1.19, 95% CI 0.96, 1.47) or the most recent HbA1c measurement throughout the trial (HR 1.21, 95% CI 0.98, 1.49). CONCLUSIONS/INTERPRETATION: Higher day-to-day fasting glycaemic variability is associated with increased risks of severe hypoglycaemia and all-cause mortality. TRIAL REGISTRATION: ClinicalTrials.gov NCT01959529.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2017. PMID: 28913575. doi:10.1007/s00125-017-4423-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。